Bio-Rad Laboratories Stock Gives Every Indication Of Being Significantly Overvalued
Should You Buy Bio-Rad Laboratories Stock After Its 50% Fall This Year? | Nasdaq
Leading Life Science Research & Clinical Diagnostics — Bio-Rad
With $2 billion in sales, 8,000 employees and stock that's jumped 48% in a year, why have you never heard of Bio-Rad (NASDAQ: BIO)? - San Francisco Business Times
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals